Online citations, reference lists, and bibliographies.
← Back to Search

Phase II Study Of Gemcitabine Plus Docetaxel As Second-Line Treatment In Malignant Pleural Mesothelioma: A Single Institution Study

Ioannis S Tourkantonis, N. Makrilia, M. Ralli, C. Alamara, I. Nikolaidis, S. Tsimpoukis, A. Charpidou, A. Kotanidou, K. Syrigos
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Objective: The combinations of cisplatin-pemetrexed and cisplatin-gemcitabine are considered the standard systemic therapy for malignant pleural mesothelioma (MPM), which is a rapidly progressive tumor. The purpose of the present study is to evaluate the efficacy, safety, and clinical benefit of the gemcitabine plus docetaxel regimen in the second-line treatment of this disease. Patients and Methods: A total of 37 patients with MPM were treated with the combination of docetaxel (80 mg/m2) and gemcitabine (1000 mg/m2) on day 1 and 14 of a 28-day cycle. The regimen was repeated for a maximum of 6 cycles or until disease progression or unacceptable toxicity. Results: There was partial response of the disease in 7 patients (18.9%), whereas it remained stable in 23 patients (62.2%) and progressed in 7 patients (18.9%). The median time to disease progression was 7 months (range: 5.8–8.2 months) with a mean survival of 16.2 months (range: 13–19.3 months). Conclusion: The biweekly administration of docetaxel and gemcitabine, along with granulocyte colony-stimulating factor support, constitutes a safe, tolerable, and convenient regimen for the treatment of MPM, suggesting that this combination may be a viable option, especially in previously treated patients.
This paper references
10.1200/JCO.2005.04.016
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
V. Georgoulias (2005)
10.1200/JCO.2006.24.18_SUPPL.5030
A randomized multicenter phase III trial of topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine for second-line treatment of recurrent ovarian cancer.
J. Sehouli (2006)
10.1093/ANNONC/MDM430
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
P. Kosmidis (2008)
Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?
N. Vogelzang (1999)
10.1200/JCO.2003.02.043
Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?
V. Rusch (2003)
10.1002/cncr.23337
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
10.1007/s12032-007-9036-9
A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer
E. Karapanagiotou (2008)
10.1016/J.LUNGCAN.2004.11.015
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
C. Porta (2005)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1179/joc.2007.19.4.438
Biweekly Administration of Docetaxel and Gemcitabine for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Study
K. Syrigos (2007)
10.1053/SONC.2002.30232
The role of gemcitabine in the treatment of malignant mesothelioma.
H. Kindler (2002)
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
M. Ralli (2009)
10.1093/jnci/78.4.785-f
European Organization for Research and Treatment of Cancer.
H. Fukuda (2000)
10.1007/s00280-006-0242-5
A phase I–II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens
C. Kosmas (2006)
10.1200/JCO.1988.6.1.147
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
K. Antman (1988)
10.1016/S1556-0864(15)30041-1
Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group
P. Kosmidis (2007)
10.1200/JCO.2008.26.15_SUPPL.5139
Interim results of a phase II trial of pemetrexed and oxaliplatin as 2nd/3rd line therapy in hormone refractory prostate cancer
T. Dorff (2008)
10.1038/sj.bjc.6600118
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
10.1016/S0959-8049(02)80018-1
Phase II trial of ZD0473 as second-line therapy in mesothelioma.
G. Giaccone (2002)
Phase II trial of carboplatin in the treatment of patients with malignant pleural mesothelioma
EK Mbidde (1986)
10.1016/S1556-0864(15)30351-8
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
10.1002/cncr.11405
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
10.1200/JCO.2003.05.123
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
K. Fizazi (2003)
10.1016/S1547-4127(04)00108-2
External beam radiation therapy for the treatment of pleural mesothelioma.
E. Baldini (2004)
Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study.
K. Syrigos (2005)
Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study.
K. Syrigos (2007)
10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
J. van Meerbeeck (1999)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1038/sj.bjc.6602010
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
V. Georgoulias (2004)
Second line chemotherapy in malignant pleural mesothelioma with oxaliplatin/gemcitabine abstract
M Serke (2006)
10.3816/CLC.2004.N.020
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
C. Belani (2004)
10.1002/cncr.22366
Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma
D. Fennell (2007)
10.1097/JTO.0B013E31802F3813
Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment
J. Sørensen (2007)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1016/J.LUNGCAN.2007.07.021
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.
V. Georgoulias (2008)
10.1093/ANNONC/MDF046
Malignant pleural mesothelioma: a phase II trial with docetaxel.
D. Vorobiof (2002)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1093/ANNONC/MDI187
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)



This paper is referenced by
10.21037/18568
Clinical efficacies of gemcitabine combined with docetaxel single or plus bevacizumab as second-line therapy for malignant pleural mesothelioma
C. Zhou (2018)
10.1016/j.lungcan.2015.06.018
Second line therapy in malignant pleural mesothelioma: A systematic review.
W. Buikhuisen (2015)
10.1159/000324454
Hypersensitivity Reactions to Docetaxel: Retrospective Evaluation and Development of a Desensitization Protocol
E. Syrigou (2011)
10.3978/j.issn.2218-6751.2014.07.01
The role of interleukin-6 in malignant mesothelioma.
S. N. Abdul Rahim (2015)
Wczesne i odległe wyniki leczenia złośliwego międzybłoniaka opłucnej na podstawie analizy 170 przypadków
Bryl Maciej (2012)
10.1007/978-3-642-10862-4_8
Chemotherapy and radiotherapy for mesothelioma.
X. Dhalluin (2011)
10.7314/APJCP.2013.14.6.3887
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
H. Mutlu (2013)
10.1016/j.pneumo.2012.12.003
Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin
J. Delourme (2013)
10.2217/LMT.14.17
Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice
G. Ceresoli (2014)
10.1007/s12032-014-0074-9
Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study
H. Mutlu (2014)
10.1016/S1877-1203(14)70610-X
Mésothéliome pleural malin : la chimiothérapie est-elle la seule option thérapeutique ?
A. Scherpereel (2014)
10.1016/S1877-1203(16)30135-5
Traitement du mésothéliome pleural malin en 2016
A. Scherpereel (2016)
10.1016/J.PNEUMO.2010.07.013
Traitement de seconde ligne dans le mésothéliome pleural malin. Étude rétrospective française (2005–2006)
J. Margery (2010)
10.1111/1759-7714.12967
Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
L. Rojas (2019)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.1007/s13665-012-0010-4
Emerging therapies for malignant pleural mesothelioma
J. Quispel-Janssen (2012)
10.1101/459065
Mesothelioma Interactome with 367 Novel Protein-Protein Interactions
Kalyani B. Karunakaran (2018)
10.1016/j.rmed.2018.06.026
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
F. Petrelli (2018)
10.1093/ejcts/ezaa158
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
10.1586/17476348.2015.1083426
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review
O. Abdel-Rahman (2015)
10.1007/978-3-030-16884-1_15
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma
L. Gianoncelli (2019)
Semantic Scholar Logo Some data provided by SemanticScholar